Table 3.
Univariate and multivariate prognostic analysis of DFS/OS in patients with ER−/PgR+ tumors
| DFS | OS | |||||
|---|---|---|---|---|---|---|
| Univariate | Multivariate | Univariate | Multivariate | |||
| P value | P value | HR (95% CI)a | P value | P value | HR (95% CI) | |
| Meno | ||||||
| Post versus Pre | 0.624 | 0.048 | 0.33 (0.11–0.99) | 0.805 | 0.556 | |
| Age | ||||||
| <50 year versus ≥50 year | 0.634 | 0.926 | 0.676 | 0.685 | ||
| Size | ||||||
| T0-1 versus T2 versus T3 | 0.093 | 0.341 | 0.158 | 0.787 | ||
| Stage | ||||||
| III versus II versus 0-I | 0.004 | 0.116 | 0.587 | 0.801 | ||
| Pathol | ||||||
| Invasive versus Non-invasive | 0.315 | 0.810 | 0.862 | 0.651 | ||
| ALN | ||||||
| Positive versus Negative | <0.001 | <0.001 | 3.87 (2.18-6.85) | 0.002 | 0.003 | 2.72 (1.39-5.30) |
| AC | ||||||
| Yes versus No | 0.858 | 0.117 | 0.475 | 0.857 | ||
| AE | ||||||
| Yes versus No | 0.628 | 0.221 | 0.111 | 0.100 | ||
| HER-2b | ||||||
| Positive versus Negative | 0.433 | 0.795 | 0.567 | 0.586 | ||
Meno menopausal status, Pathol Pathologic, AC Adjuvant chemotherapy, AE Adjuvant endocrine therapy of TAM
a HR hazard ratio, CI confidence interval
bPositive indicating HER-2 ++~+++ by IHC; negative indicating HER-2 −~+ by IHC